Top Markets
#1 Cortex Cortex +32.35%
#2 龙虾 (Lobster) 龙虾 (Lobster) +14.99%
#3 MarsCoin MarsCoin +12.34%
#4 Akedo Akedo +11.99%
#5 Pons Pons +9.79%
#6 EXOD EXOD +9.04%
#7 The Black Bull The Black Bull +8.03%
#8 Seeker Seeker +7.28%
#9 Official Trump Official Trump +7.06%
#10 Solstice Solstice +6.70%
Coin of the day
Cortex Cortex
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Ascentage Pharma Group International Ascentage Pharma Group International

Ascentage Pharma Group International

AAPG
Classifica tra le azioni #7070
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology... Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
Prezzo delle azioni
$18.66
Ultima sincronizzazione: 2026-08-27
Capitalizzazione di mercato
$1.73B
Variazione (1 giorno)
10.41%
Variazione (1 anno)
-54.63%
Paese
CN
Scambia Ascentage Pharma Group International (AAPG)

Categoria

Healthcare
Rapporto P/E per Ascentage Pharma Group International (AAPG)
Rapporto P/E al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Ascentage Pharma Group International, il rapporto P/E attuale (TTM) è 0. Alla fine del 2026, il rapporto P/E era 0.
Storico del rapporto P/E per Ascentage Pharma Group International da 2026 a 2026
Rapporto P/E alla fine di ogni anno
Anno Rapporto P/E Cambia
Non abbastanza dati per le date fornite.
Rapporto P/E per aziende simili o concorrenti
Azienda P/E Ratio Differenza del P/E Ratio Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Come leggere un P/E ratio?

Il rapporto Prezzo/Utile (P/E) misura la relazione tra il prezzo delle azioni di una società e i suoi utili per azione.
Un P/E basso ma positivo indica un'azienda che genera alti profitti rispetto alla sua valutazione attuale e potrebbe essere sottovalutata. Un'azienda con un P/E negativo elevato (vicino allo 0) segnala forti perdite rispetto alla valutazione.

Le aziende con un P/E superiore a 30 o negativo sono generalmente considerate "azioni di crescita", cioè ci si aspetta che crescano o diventino redditizie.

Le aziende con un P/E positivo inferiore a 10 sono considerate "azioni di valore", ossia già molto redditizie ma con scarse prospettive di crescita.